Brokers Issue Forecasts for ALX Oncology FY2025 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of ALX Oncology in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings per share of ($2.21) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

ALXO has been the topic of a number of other reports. Jefferies Financial Group downgraded shares of ALX Oncology from a “buy” rating to a “hold” rating and reduced their target price for the stock from $12.00 to $2.00 in a research report on Thursday, December 19th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a report on Wednesday, December 18th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.50.

ALX Oncology Stock Down 22.5 %

ALXO stock opened at $1.40 on Thursday. The company has a market capitalization of $73.57 million, a price-to-earnings ratio of -0.45 and a beta of 0.98. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The business’s 50 day moving average price is $1.61 and its two-hundred day moving average price is $2.43. ALX Oncology has a fifty-two week low of $1.19 and a fifty-two week high of $17.83.

Insiders Place Their Bets

In related news, Director Rekha Hemrajani purchased 30,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, with a total value of $46,500.00. Following the acquisition, the director now directly owns 33,000 shares in the company, valued at $51,150. The trade was a 1,000.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 14,443 shares of company stock valued at $23,309. Corporate insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALXO. Marshall Wace LLP lifted its holdings in shares of ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after buying an additional 514,133 shares during the period. Privium Fund Management B.V. grew its stake in shares of ALX Oncology by 28.2% during the 3rd quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after purchasing an additional 112,093 shares during the period. Renaissance Technologies LLC increased its position in shares of ALX Oncology by 87.2% during the 2nd quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after purchasing an additional 204,100 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of ALX Oncology in the third quarter worth approximately $578,000. Finally, Point72 Asset Management L.P. bought a new stake in ALX Oncology during the second quarter valued at approximately $1,834,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.